Enteryx for gastroesophageal reflux disease.
The Enteryx procedure is an endoscopic injectable treatment for the management of gastroesophageal reflux disease symptoms. Enteryx was approved by the US Food and Drug Administration in April 2003 for patients who respond to, and require daily pharmacologic therapy with proton-pump inhibitors. Although gastroesophageal reflux disease is rarely life threatening, symptoms are often chronic and disabling. Therefore, safe and cost-effective alternative treatments for chronic gastroesophageal reflux disease are sought by patients, physicians and payers. Multicenter clinical trials have demonstrated that the Enteryx procedure safely and effectively eliminates, or significantly reduces, proton-pump inhibitor use in approximately 84% of patients at 1 year, and 72% of patients at 2 years.
Johnson
David A
DA
Division of Gastroenterology, Eastern Virginia School of Medicine, Norfolk, VA 23501, USA. dajevms@aol.com
D002986:Clinical Trials as Topic; D019544:Equipment Failure Analysis; D004943:Esophagogastric Junction / Q000473:pathology / Q000601:surgery*; D005764:Gastroesophageal Reflux / Q000473:pathology / Q000628:therapy*; D005773:Gastroscopy / Q000379:methods*; D006801:Humans; D007267:Injections; D011145:Polyvinyls / Q000008:administration & dosage* / Q000627:therapeutic use*; D011474:Prosthesis Design; D019919:Prosthesis Implantation / Q000379:methods*; D013673:Technology Assessment, Biomedical; D016896:Treatment Outcome
D011145:Polyvinyls; C020320:ethylene-vinyl alcohol copolymer